Menu Search
Equities

KALA BIO Inc

KALA:NAQ

KALA BIO Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.95
  • Today's Change-0.14 / -1.97%
  • Shares traded50.37k
  • 1 Year change+25.59%
  • Beta-2.1534
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year KALA BIO Inc had revenues fall -100.00% from 3.89m to 0.00, though the company grew net income from a loss of 44.82m to a smaller loss of 42.20m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-60.45%
Return on equity-248.11%
Return on investment-78.16%
More ▼

Cash flow in USDView more

In 2023, cash reserves at KALA BIO Inc fell by 19.85m. Cash Flow from Financing totalled 8.51m or -- of revenues. In addition the company used 27.93m for operations while cash used for investing totalled 429.00k.
Cash flow per share-13.84
Price/Cash flow per share--
Book value per share2.98
Tangible book value per share2.98
More ▼

Balance sheet in USDView more

KALA BIO Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 1.56% of the market capitalization can be attributed to its 50.90m and debt could be paid in full if management chose.
Current ratio3.07
Quick ratio--
Total debt/total equity2.54
Total debt/total capital0.7174
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.